Yongxia Guan

Yongxia Guan


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
CSChenghong Sun
Chenghong Sun
HLHong-Bao Liang
Hong-Bao Liang
YZYun Zhao
Yun Zhao
SLShirong Li
Shirong Li
XLXiangzi Li
Xiangzi Li
GZGuimin Zhang
Guimin Zhang


5 November 2023 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
NZNa Zhang
Na Zhang
FLFengyi Lv
Fengyi Lv
HXHe Xiao
He Xiao
BYBojiao Yi
Bojiao Yi
MSMingguo Shao
Mingguo Shao
GZGuimin Zhang
Guimin Zhang

30 September 2024 in Journal of Chromatography B
Verified
Journal Article
Closed access
NZNa Zhang
Na Zhang
DGDong Guo
Dong Guo
NGNa Guo
Na Guo
DYDawei Yang
Dawei Yang
HYHan Yan
Han Yan
GZGuimin Zhang
Guimin Zhang

11 October 2024 in Chinese Medicine
Verified
Journal Article
Open access
PDF file
JYJiaying Yang
Jiaying Yang
HXHe Xiao
He Xiao
JYJingchun Yao
Jingchun Yao
PZPin Zhang
Pin Zhang
BYBojiao Yi
Bojiao Yi
GZGuimin Zhang
Guimin Zhang
Background: Slow transit constipation (STC) is highly prevalent and has rising incidence. Shouhui Tongbian capsule (SHTB) is a traditional Chinese Medicine formula with extensive and highly efficacious usage in STC treatment, however, its mechanism of action, especially the regulation of microbiome and lipid metabolites, remains unclear. Methods: After quality control of SHTB using LC‒MS to obtain its material basis, we tried to elucidate the cohesive modulatory network of SHTB against STC using hyphenated methods from microbiomics, lipidomics, mass spectrometry imaging (MSI) and molecular methods. Results: SHTB could repair intestinal barrier damage, reduce systemic inflammation and increase intestinal motility in a diphenoxylate-induced STC rat model. Based on 16S rDNA sequencing results, SHTB rehabilitated the abnormal changes in Alloprevotella, Coprococcus, Marvinbryantia, etc., which were associated with STC symptoms. Meanwhile, microbial functional prediction showed that lipid metabolism was improved with SHTB administration. The differential lipids, including fatty acids, lysophosphatidylcholine, phosphatidylcholine, sphingomyelin triglyceride and ceramide, that are closely related to STC disease and SHTB efficacy. Furthermore, SHTB significantly reversed the abnormal expression of these key target enzymes in colon samples, including CTP-phosphocholine cytidylyltransferase, CTP-phosphoethanolamine cytidylyltransferase, phosphatidic acid phosphatase, acid sphingomyelinase etc. Conclusions: Combined analysis demonstrated that SHTB reducing lipid accumulation and recovery of intestinal microbial homeostasis was the critical mechanism by which SHTB treats STC.

28 May 2024 in Aging
Verified
Journal Article
Open access
PDF file
YLYanling Li
Yanling Li
QYQingying Yu
Qingying Yu
HPHuiyuan Peng
Huiyuan Peng
XMXie Mingjun
Xie Mingjun
WXWenHua Xu
WenHua Xu
PSPeng Sun
Peng Sun
Intracerebral hemorrhage (ICH) can induce intensive oxidative stress, neuroinflammation, and brain cell apoptosis. However, conventional methods for ICH treatment have many disadvantages. There is an urgent need for alternative, effective therapies with minimal side effects. Pharmacodynamics experiment, molecular docking, network pharmacology, and metabolomics were adopted to investigate the treatment and its mechanism of Jingfang Granules (JFG) in ICH. In this study, we investigated the therapeutic effects of JFG on ICH using behavioral, brain water content and Magnetic resonance imaging experiments. However, the key active component and targets of JFG remain unknown. Here we verified that JFG was beneficial to improve brain injury after ICH. A network pharmacology analysis revealed that the anti-inflammatory effect of JFG is predominantly mediated by its activation of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway through Luteolin, (+)-Anomalin and Phaseol and their targeting of AKT1, tumor necrosis factorα (TNF-α), and interleukin-1β (IL-1β). Molecular docking analyses revealed an average affinity of −8.633 kcal/mol, indicating a binding strength of less than −5 kcal/mol. Metabolomic analysis showed that JFG exerted its therapeutic effect on ICH by regulating metabolic pathways, such as the metabolism of taurine and hypotaurine, biosynthesis of valine, leucine, and isoleucine. In conclusion, we demonstrated that JFG attenuated neuroinflammation and BBB injury subsequent to ICH by activating the PI3K/Akt signaling pathway.